Koyfin Home > Directory > Health Care > Amag Pharmaceuticals > Long-Term Debt

Amag Pharmaceuticals Long-Term Debt Chart (AMAG)

Amag Pharmaceuticals annual/quarterly Long-Term Debt from 2014 to 2020.
  • Amag Pharmaceuticals Long-Term Debt for the quarter ending June 06, 2020 was $285m a 4.21% increase of 12m year over year
  • Amag Pharmaceuticals Long-Term Debt for the last 12 months ending June 06, 2020 was $285m a 4.21% increase of 12m year over year
  • Amag Pharmaceuticals Annual Long-Term Debt for 2019 was $277m a 5.45% increase of 15m from 2018
  • Amag Pharmaceuticals Annual Long-Term Debt for 2018 was $262m a -180.49% decrease of -473m from 2017
  • Amag Pharmaceuticals Annual Long-Term Debt for 2017 was $735m a -31.40% decrease of -231m from 2016
Other Cash Flow Metrics:
  • Amag Pharmaceuticals Cash Flow from Operations for the quarter ending December 12, 2018 was $-34m a 162.36% decrease of -55m year over year
  • Amag Pharmaceuticals Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-31m a 66.13% decrease of -21m year over year
  • Amag Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $122m a -29.53% decrease of -36m year over year
View Chart On Koyfin

Quarterly AMAG Long-Term Debt Data

06/2020$285m
03/2020$281m
12/2019$277m
09/2019$273m
06/2019$269m
03/2019$266m
12/2018$262m
09/2018$258m
06/2018$722m
03/2018$718m

Annual AMAG Long-Term Debt Data

2019$277m
2018$262m
2017$735m
2016$965m
2015$974m
2014$461m